1-(Aminomethyl)-4-isocyanobenzene | 1258405-70-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(Aminomethyl)-4-isocyanobenzene
• 英文别名: (4-isocyanophenyl)methanamine
• CAS: 1258405-70-7
• 化学式: C₈H₈N₂
• 分子量: 132.165
• InChiKey: YRPQEGYDPCXHSA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  30.4
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  氨基吡嗪 、 1-(Aminomethyl)-4-isocyanobenzene 、 苯甲醛 在 scandium tris(trifluoromethanesulfonate) 作用下， 生成 N-[4-(aminomethyl)phenyl]-2-phenylimidazo[1,2-a]pyrazin-3-amine
  参考文献：
  名称：

  The Discovery of furo[2,3-c]pyridine-based indanone oximes as potent and selective B-Raf inhibitors

  摘要：

  Virtual and high-throughput screening identified imidazo[1,2-a]pyrazines as inhibitors of B-Raf. We describe the rationale, SAR, and evolution of the initial hits to a series of furo[2,3-c]pyridine indanone oximes as highly potent and selective inhibitors of B-Raf. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.12.039

文献信息

• Diaryl piperidines as CB1 modulators
  申请人：Scott D. Jack

  公开号：US20070203183A1

  公开（公告）日：2007-08-30

  A compound having the general structure of Formula (I): or a pharmaceutically acceptable salt, solvate, or ester thereof, are useful in treating diseases, disorders, or conditions such as metabolic syndrome (e.g., obesity, waist circumference, lipid profile, and insulin sensitivity), neuroinflammatory disorders, cognitive disorders, psychosis, addictive behavior, gastrointestinal disorders, and cardiovascular conditions.

  具有通式（I）的一种化合物，或其药学上可接受的盐、溶剂合物或酯，可用于治疗代谢综合征（例如肥胖、腰围、脂质谱和胰岛素敏感性）、神经炎症性疾病、认知障碍、精神病、成瘾行为、胃肠道疾病和心血管疾病等疾病、疾病或症状。
• [EN] 2-ARYL- AND 2-HETEROARYLTHIAZOLYL COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF<br/>[FR] COMPOSÉS DE 2-ARYL- ET DE 2-HÉTÉROARYL-THIAZOLYLE, LEURS PROCÉDÉS DE PRÉPARATION ET D'UTILISATION
  申请人：WYETH CORP

  公开号：WO2009120826A1

  公开（公告）日：2009-10-01

  The present invention discloses fused bicyclic 2-aryl- or 2-heteroarylthiazolyl compounds and their pharmaceutically acceptable salts and esters thereof, which are useful for inhibiting the growth of cancerous cells, inhibiting human breast carcinoma tumor growth in particular and to treat diseases or disorders associated with securin, including elevated securin levels.

  本发明揭示了融合的双环2-芳基或2-杂环芳基噻唑基化合物及其药用盐和酯，这些化合物对抑制癌细胞的生长、特别是抑制人类乳腺癌肿瘤的生长以及治疗与分泌蛋白相关的疾病或紊乱，包括高水平的分泌蛋白水平具有用处。
• N-BIPHENYLMETHYLINDOLE MODULATORS OF PPARG
  申请人：Kamenecka Theodore Mark

  公开号：US20120309757A1

  公开（公告）日：2012-12-06

  The invention provides molecular entities that bind with high affinity to PPARG (PPARγ), inhibit kinase-mediated, e.g., cdk5-mediated, phosphorylation of PPARG, but do not exert an agonistic effect on PPARG. Compounds of the invention can be used for treatment of conditions in patients wherein PPARG plays a role, such as diabetes, insulin resistance, impaired glucose tolerance, pre-diabetes, hyperglycemia, hyperinsulinemia, obesity, or inflammation. In methods of treatment of these conditions using a compound of the invention, the compound can avoid producing side effects of significant weight gain, edema, impairment of bone growth or formation, or cardiac hypertrophy, or any combination thereof, in the patient receiving the compound. Methods of preparation of the compounds, bioassay methods for evaluating compounds of the invention as non-agonistic PPARG binding compounds, and pharmaceutical compositions are also provided.

  该发明提供了与PPARG（PPARγ）结合亲和力高的分子实体，抑制激酶介导的，例如cdk5介导的PPARG磷酸化，但不对PPARG产生激动作用。该发明的化合物可用于治疗患有PPARG起作用的疾病的患者，如糖尿病、胰岛素抵抗、糖耐量受损、糖尿病前期、高血糖、高胰岛素血症、肥胖或炎症。在使用该发明的化合物治疗这些疾病的方法中，该化合物可以避免在接受该化合物的患者中产生明显体重增加、水肿、骨生长或形成受损、心肌肥大或上述任何组合的副作用。该发明还提供了化合物的制备方法、用于评估该发明的化合物作为非激动性PPARG结合化合物的生物测定方法，以及制药组合物。
• 2-Aryl- and 2-Heteroarylthiazolyl Compounds, Methods for Their Preparation and Use Thereof
  申请人：Zhang Nan

  公开号：US20090270363A1

  公开（公告）日：2009-10-29

  The present invention discloses fused bicyclic 2-aryl- or 2-heteroarylthiazolyl compounds and their pharmaceutically acceptable salts and esters thereof, which are useful for inhibiting the growth of cancerous cells, inhibiting human breast carcinoma tumor growth in particular and to treat diseases or disorders associated with securin, including elevated securin levels.

  本发明公开了融合的双环2-芳基-或2-杂环基硫唑基化合物及其药学上可接受的盐和酯，其对抑制癌细胞生长、特别是对抑制人类乳腺癌肿瘤生长以及治疗与分离素有关的疾病或疾病相关障碍，包括升高的分离素水平具有用处。
• MATRIX METALLOPROTEINASE INHIBITORS AND METHODS FOR THE TREATMENT OF PAIN AND OTHER DISEASES
  申请人：SUCHOLEIKI Irving

  公开号：US20150274702A1

  公开（公告）日：2015-10-01

  The present invention relates generally to bis-amide containing MMP inhibiting compounds, and more particularly to selectively deuterated bis-amide MMP-13 inhibiting compounds that exhibit increased stability or potency in relation to currently known MMP-13 inhibitors. Additionally, the present invention relates to methods for treating pain and inflammation in a patient comprising administering to the patient a pain-reducing effective amount of a present compound.

  本发明一般涉及含有MMP抑制化合物的双酰胺，更具体地涉及具有选择性氘代的双酰胺MMP-13抑制剂，其相对于当前已知的MMP-13抑制剂表现出增强的稳定性或效力。此外，本发明还涉及一种治疗患者疼痛和炎症的方法，包括向患者施用本化合物的减痛有效量。